$75,000,000 new notes w/ possible limited or no maturity
".....in one or more offerings up to a total aggregate offering price of $75,000,000 on terms to be determined at the time of sale.....maturity, if applicable; "
"To approve an amendment to the Company's Amended Articles of Incorporation to implement one or more Reverse Stock Splits of the Company's common stock at an aggregate ratio of not less than one-for-five and not more than one-for-twenty, within the discretion of the Board of Directors, at any time or from time-to-time prior to July [__], 2017;"
"To approve an amendment to the Company's Amended Articles of Incorporation to increase the authorized number of shares of common stock and preferred stock to 950,000,000 and 50,000,000, respectively"
AS is maxed. Issued warrants and CD notes that mature soon need to be able to convert.
"As of March 24, 2016, the number of shares of the Registrant's Common Stock outstanding was 463,036,181, which assumes the conversion of 100 shares of Series A Preferred Stock, convertible at any time into 100 shares of Common Stock, 16,150,000 shares of Series B Preferred Stock, convertible into 86,956,857 shares of Common Stock, and 32,276,008 shares of Common Stock issuable upon the exercise of all of our outstanding warrants."
On March 10, 2016, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Therapeutics Medical, LLC (the "Seller"), pursuant to which the Company acquired from the Seller certain assets (the "Assets") related to a business engaged in the research, development, and marketing of nutraceutical supplements. The Purchase Agreement provides that the Company will issue a Convertible Promissory Note (the "Convertible Promissory Note") due September 10, 2017, to the Seller in the principal amount of $1.25 million for the purchase of the Assets. The Convertible Promissory Note accrues interest at the rate of one percent per annum, and is convertible into shares of the Company's common stock at a conversion price equal to 90% of the average of the lowest three (3) volume-weighted average prices of one share of common stock for the five (5) consecutive trading days prior to the conversion date.
"Michael James, CEO of NRTI & CFO for TRTC, quietly and secretively created this new entity, Therapeutics Medical, LLC, that TRTC is now acquiring through this backdoor deal to get ahold of NRTI's entire CBD program, without involving or fairly compensating NRTI or its shareholders. This scheme was well planned out and they have tried to keep it hidden until it was finalized. "
NAHASS MICHAEL Officer 04/18/2016 Sell direct 300,000 0.4825 3100796 NAHASS MICHAEL Officer 04/15/2016 Sell direct 100,000 0.4825 3400796 VANDEVREDE MIKE Director 04/12/2016 Sell direct 100,000 0.3726 1,056,944 VANDEVREDE STEVE Director 04/11/2016 Sell direct 150,000 0.3475 669,444 VANDEVREDE STEVE Director 04/08/2016 Sell direct 92,500 0.3782 819,444 NAHASS MICHAEL Officer 04/07/2016 Sell direct 100,000 0.4040 3,500,796 VANDEVREDE KEN Officer 04/06/2016 Sell direct 25,000 0.3500 522,071 NAHASS MICHAEL Officer 04/06/2016 Sell direct 200,000 0.3690 3,600,796 VANDEVREDE KEN Officer 04/05/2016 Sell direct 25,000 0.3105 547,071 ALMSTEIER AMY Officer 04/04/2016 Sell direct 303,427 0.2953 996,078 NAHASS MICHAEL Director 04/04/2016 Sell direct 400,000 0.3060 3,800,796 VANDEVREDE KEN Officer 04/04/2016 Sell direct 125,000 0.2708 572,071 ALMSTEIER AMY Officer 04/01/2016 Sell direct 274,800 0.2701 1,299,505
News 
Market Data 
Discover 
AI
